Browsing by Author "Tadros S.A."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Serum human leukocyte antigen-G and soluble interleukin 2 receptor levels in acute lymphoblastic leukemic pediatric patients
    (Asian Pacific Organization for Cancer Prevention, 2012) Motawi T.M.K.; Zakhary N.I.; Salman T.M.; Tadros S.A.; Biochemistry Department; Faculty of Pharmacy; Egypt; Cancer Biology Department; National Cancer Institute; Egypt; Cairo University; Egypt; Al-Azhar University; Egypt; MSA University; Egypt
    Aims and Background: Human leukocyte antigen-G and interleukin-2 receptor play pivotal roles in the proliferation of lymphocytes, and thus generation of immune responses. Their overexpression has been evidenced in different malignant hematopoietic diseases. This study aimed to validate serum soluble human leukocyte antigen-G (sHLA-G) and serum soluble interleukin-2 receptor (sIL-2R) as an additional tool for the diagnosis and follow up of acute lymphoblastic leukemia (ALL). Subjects and Methods: Both markers were determined by ELISA in the serum of 33 ALL pediatric patients before treatment and after intensification phase of chemotherapy as well as in the serum of 14 healthy donors that were selected as a control group. Results: ALL patients showed abnormal CBC and high serum lactate dehydrogenase, which were improved after chemotherapy. Also, there was a non-significant increase in serum sHLA-G in ALL patients compared with the control group. However, after chemotherapy, sHLA-G was increased significantly compared with before treatment. On the other hand, serum sIL-2R in ALL patients was increased significantly compared with the control group. After chemotherapy, sIL-2R decreased significantly compared with before treatment. Conclusions: From these results it could be suggested that measurement of serum sHLA-G might be helpful in diagnosis of ALL, while sIL-2R might be useful in diagnosis and follow-up of ALL in pediatric patients.
  • Thumbnail Image
    Item
    Significance of Serum Survivin and -31G/C Gene Polymorphism in the Early Diagnosis of Breast Cancer in Egypt
    (Elsevier Inc., 2019) Motawi T.M.K.; Zakhary N.I.; Darwish H.A.; Abdalla H.M.; Tadros S.A.; Department of Biochemistry; Faculty of Pharmacy; Cairo University; Cairo; Egypt; Department of Cancer Biology; National Cancer Institute; Cairo University; Cairo; Egypt; Board of Trustees; The British University in Egypt (BUE); Cairo; Egypt; Department of Pharmacology; Toxicology; and Biochemistry; Faculty of Pharmaceutical Sciences and Pharmaceutical Industries; Future University; Cairo; Egypt; Department of Surgical Oncology; National Cancer Institute; Cairo University; Cairo; Egypt; Department of Biochemistry; Faculty of Pharmacy; October University for Modern Sciences and Arts (MSA); October; Egypt
    The majority of breast cancer cases are discovered in later disease stages, thus affecting survival rate. We studied the impact of survivin -31 G/C single nucleotide polymorphism and its serum level alteration. Minor allele C and the GC + CC genotype occurred more frequently in breast cancer patients; further, increased breast cancer risk with associated with elevated serum survivin level. These data could help in early diagnosis and understanding of the pathogenesis of breast cancer. 2019 Elsevier Inc.Background: Breast cancer is one of the most relevant malignancies among women. Molecular abnormalities in promotor region of survivin gene may account for overexpression of survivin and increased breast cancer risk. This study aimed to explore the potential association between survivin promotor gene -31G/C single nucleotide polymorphism (rs9904341) and its serum level alteration on one hand, and the risk of breast cancer in Egyptian patients on the other hand. It also aimed to assess the usefulness of survivin as an early noninvasive diagnostic biomarker and in breast cancer staging. Patients and Methods: A total of 135 patients with physically and pathologically confirmed breast cancer and 40 unrelated control subjects as well as 40 patients with benign breast mass were recruited from the early detection unit at National Cancer Institute, Cairo University. Genotyping was performed using allelic discrimination probes by real-time quantitative PCR and serum survivin by enzyme-linked immunosorbent assay. Results: The minor allele C of -31G/C survivin single nucleotide polymorphism was more frequent in breast cancer patients (19.3%) compared to the control group (7.5%). Furthermore, subjects with the GC + CC genotype were at increased risk of breast cancer compared to the GG genotype of the control group and also the benign group. Moreover, those patients exhibited higher serum levels of survivin compared to GG genotype. There was also significant elevation of serum survivin in different breast cancer stages. Conclusion: Genetic variation in -31G/C of the survivin gene may contribute to the disposition of breast cancer in the Egyptian population. Serum survivin alteration played a pivotal role in the pathogenesis of breast cancer. 2019 Elsevier Inc.